Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment

International Journal of Medical Sciences

Volumn 10, Issue 8, 2013, Pages 1015-1021

  Nakamura, Masato ^a   Kanda, Tatsuo ^a   Miyamura, Tatsuo ^a   Wu, Shuang ^a   Nakamoto, Shingo ^a   Yo Kosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

ALT; HCV; IL28B; Peginterferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ANALYSIS; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IL28B GENE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME;

ALT; HCV; IL28B; PEGINTERFERON; RIBAVIRIN.;

ADULT; AGED; ALANINE TRANSAMINASE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84879285626     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6402     Document Type: Article

References (45)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-982.
2. Muir AJ, Bornstein JD, Killenberg PG, et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004; 350: 2265-2271.
3. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010; 4: 548-561.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49: 1335-1374.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55: 245-264.
6. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012; 55: 409-435.
7. Kumada H, Toyoda J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012; 56: 78-84.
8. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2012 [Epub ahead of print].
9. Hadziyannis SJ, Papatheodoridis GV. Peginterferon-alpha2a (40kDa) for chronic hepatitis C. Expert Opin Pharmacother. 2003; 4: 541-551.
10. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002; 54: 547-70.
11. Silva MO, Reddy KR, Jeffers LJ, et al. Interferon-induced chronic active hepatitis? Gastroenterology. 1991; 101(3): 840-842.
12. Sindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology. 1992; 102(4 Pt 1): 1406-1408.
13. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 1995; 108: 1770-1777.
14. Cervoni JP, Degos F, Marcellin P, et al. Acute hepatitis induced a-interferon, associated with viral clearance, in chronic hepatitis C. J Hepatol. 1997; 17: 1113-1116.
15. Lorke J, Erhardt A, Haussinger D. Induction of autoinnune hepatitis by pegylated interferon alfa-2b in chronic hepatitis C. Clin Gastroenterol Hepatol. 2004; 2: 20.
16. Chang KM, Rehermann B, Chisari FV. Immunopathology of hepatitis C. Springer Semin Immunopathol. 1997; 19: 57-68
17. Meyer K, Ait-Goughoulte M, Keck ZY, Foung S, Ray R. Antibody-dependent enhancement of hepatitis C virus infection. J Virol. 2008; 82: 2140-2149.
18. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996; 24: 38-47.
19. Mishiro S, Takeda K, Hoshi Y, et al. An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen. Autoimmunity. 1991; 10: 269-273.
20. Kogre T, Ueno Y, Fukushima K, et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol. 2007;13: 4394-4397.
21. Kato H, Ikeuchi H, Nakamura M. Acute exacerbation of liver disease induced by peglated interferon alpha2a treatment for chronic hepatitis C. International Journal of Clinical Medicine. 2010; 1: 1-5
22. Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. 2011; 43: 666-667.
23. Kanda T, Imazeki F, Yonemitsu Y, et al. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat. 2011; 18: q292-297.
24. Miyauchi T, Kanda T, Imazeki F, et al. Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. Hepatol Int. 2013; 7: 144-152.
25. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology. 1994; 19: 1347-1353.
26. Miyamura T, Kanda T, Nakamoto S, et al. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PloS One. 2011; 6: e28617.
27. Miyamura T, Kanda T, Nakamoto S, et al. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses. 2012; 4: 1264-1278.
28. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123: 1061-1069.
29. Agundez JA, Garcia-Martin E, Maestro ML, et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PloS One. 2012; 7: e37998.
30. Nunnari G, Pinzone MR, Cacopardo B. Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. J Viral Hepat. 2013; 20: e131-e137.
31. Noureddin M, Wright EC, Alter H, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology. 2013; [Epub ahead of print].
32. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VH. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007; 14: 721-729.
33. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009; 49: 22-31.
34. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361: 580-593.
35. Rumi MG, Aqhemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010; 138: 108-115.
36. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010; 138: 116-122.
37. Witthoeft T, Hueppe D, John C, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE study. J Viral Hepat. 2010; 17:459-468.
38. Award T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systemic review of randomized trials. Hepatology. 2010; 51: 1176-1184.
39. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401.
40. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide asssociation of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41: 1105-1109.
41. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41: 1100-1104.
42. Nakamoto S, Kanda T, Imazeki F, et al. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol. 2011; 46: 955-961.
43. Aoki YH, Ohkoshi S, Yamagiwa S, et al. Characterization of elevated alanine amino transferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. Hepatol Res. 2011; 41: 118-125.
44. Kanda T, Yokosuka O, Imazeki F, Yokosuka O. Acute hepatitis C virus infection, 1986-2001: a rare cause of fulminant hepatitis in Chiba, Japan. Hepatogastroenterology. 2004; 51: 556-558.
45. Read AE, Donegan E, Lake J, et al. Hepatitis C in patients undergoing liver transplantation. Ann Intern Med. 1991; 114: 282-284.